TY - JOUR
T1 - Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy
AU - Rothberg, Bonnie E.Gould
AU - Grooms, Mary C.
AU - Dharnidharka, Vikas R.
PY - 2006/9
Y1 - 2006/9
N2 - BACKGROUND: Kidney angiomyolipomas are benign but progressive tumors consisting of smooth muscle, fat, and vascular elements, commonly associated with the tuberous sclerosis complex. Angiomyolipomas express estrogen and progesterone receptors and have been reported to increase in size in pregnancy. CASE: A 15-year-old girl with stable angiomyolipomas of tuberous sclerosis complex was treated for menorrhagia with estrogen/progestin oral contraceptive pills. During the 12 months of contraceptive therapy, a new 4-cm exophytic angiomyolipoma developed that required selective arterial embolization to reduce its risk of spontaneous rupture. CONCLUSION: Treating menorrhagia with exogenous hormonal therapy in women with tuberous sclerosis complex should be accompanied by regular renal imaging to reduce the risk of an unanticipated angiomyolipoma-related adverse event. Alternate nonhormonal therapies for menorrhagia may also be considered.
AB - BACKGROUND: Kidney angiomyolipomas are benign but progressive tumors consisting of smooth muscle, fat, and vascular elements, commonly associated with the tuberous sclerosis complex. Angiomyolipomas express estrogen and progesterone receptors and have been reported to increase in size in pregnancy. CASE: A 15-year-old girl with stable angiomyolipomas of tuberous sclerosis complex was treated for menorrhagia with estrogen/progestin oral contraceptive pills. During the 12 months of contraceptive therapy, a new 4-cm exophytic angiomyolipoma developed that required selective arterial embolization to reduce its risk of spontaneous rupture. CONCLUSION: Treating menorrhagia with exogenous hormonal therapy in women with tuberous sclerosis complex should be accompanied by regular renal imaging to reduce the risk of an unanticipated angiomyolipoma-related adverse event. Alternate nonhormonal therapies for menorrhagia may also be considered.
UR - http://www.scopus.com/inward/record.url?scp=33748115970&partnerID=8YFLogxK
U2 - 10.1097/01.AOG.0000188062.13749.ef
DO - 10.1097/01.AOG.0000188062.13749.ef
M3 - Article
C2 - 17018483
AN - SCOPUS:33748115970
SN - 0029-7844
VL - 108
SP - 734
EP - 736
JO - Obstetrics and gynecology
JF - Obstetrics and gynecology
IS - 3 II
ER -